KRAS G12C

Term: KRAS G12CDefinition: A specific mutation in the KRAS gene where the amino acid glycine at position 12 is replaced by cysteine, commonly found in various cancers including lung cancer.Phonetic Pronunciation: (KAY-rass GEE-twelve-SEE)Origin: The term KRAS derives from the Kirsten rat sarcoma virus, which was discovered to carry this oncogene. The nomenclature 'G12C' indicates the specific mutation at the 12th codon of the KRAS gene, substituting glycine (G) with cysteine (C). This mutation's designation follows standard genetic nomenclature for describing point mutations.Significance in Asbestos Context: KRAS G12C mutations have been linked to lung cancers in individuals exposed to asbestos. Understanding the prevalence of this mutation in asbestos-related cancers can aid in targeted therapies and personalized treatment plans for affected individuals.Example Sentence: Recent studies have shown that a subset of lung cancer patients with a history of asbestos exposure carry the KRAS G12C mutation, which may influence their treatment options.Related Terms: Lung cancer, oncogene, mutation, targeted therapy, asbestos-related disease.Notes: - KRAS G12C is just one of many possible mutations in the KRAS gene. - Not all lung cancers associated with asbestos exposure will have this specific mutation. - The presence of this mutation can affect the prognosis and treatment efficacy.